| Document |
Document Title |
|
WO/2020/232445A1 |
The disclosure is directed, inter alia, to compounds and compositions that modulate pyrimidine nucleotide biosynthetic pathways, such as the pyrimidine nucleoside salvage pathway and the pyrimidine de novo pathway, and to their use in tr...
|
|
WO/2020/232255A1 |
Compounds described herein may be used for the treatment of neurodegenerative diseases linked to protein misfolding, including prion diseases, Alzheimers' disease, Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS), and als...
|
|
WO/2020/231496A1 |
Provided herein, are methods of making a thi azoline anti-hyperalgesic, Compound 1, and polymorphs, thereof. The methods described herein use inexpensive reagents and are capable of providing Compound 1 in commercial-scale quantities. Al...
|
|
WO/2020/229688A1 |
A pharmaceutical composition or combination product comprising certain thiazoles in combination with certain protein kinase inhibitors, in particular phosphatidylinositol-4,5-bisphosphate 3-kinase inhibitors (PI3K), such as buparlisib. T...
|
|
WO/2020/227168A1 |
The present disclosure is directed to compounds of formulas (I) - (VII), which are useful as modulators of TRABID. The compounds are further useful in the inhibition of TRABID and the treatment of diseases or disorders associated with th...
|
|
WO/2020/222118A1 |
Non-aromatic fluoroalkenyl heterocyclic compounds having general formula (I), agronomic compositions containing said compounds having formula (I) and their use for the control of nematodes in agricultural crops, are described.
|
|
WO/2020/219258A1 |
Disclosed herein are aztreonam derivatives, therapeutic methods of using the aztreonam derivatives, and methods of synthesizing aztreonam derivatives. The aztreonam derivatives can be administered orally to provide orally bioavailable az...
|
|
WO/2020/216780A1 |
The invention relates to a method for producing N,N-disubstituted benzthiazolyl-sulfenamides.
|
|
WO/2020/216298A1 |
Disclosed are a compound as shown in formula I, a stereoisomer thereof, and a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing the compound of formula I and use of th...
|
|
WO/2020/209933A1 |
Disclosed herein are inhibitors of the Notch transcriptional activation complex, and methods for their use in treating or preventing diseases, such as cancer. The inhibitors described herein can include compounds of Formula (I) and pharm...
|
|
WO/2020/204624A1 |
The present invention provides a novel prodrug of a mirabegron compound or pharmaceutically acceptable salts thereof, a pharmaceutical composition comprising same as an active ingredient, and a pharmaceutical use of same for treating or ...
|
|
WO/2020/201538A1 |
The present invention relates to a complementation system comprising two fragments of photoactive yellow protein (PYP), or truncated fragments thereof, and its use with a fluorogenic hydroxybenzylidene rhodanine (HBR) analog for detectin...
|
|
WO/2020/204041A1 |
Provided is a colored dispersion that contains (A) a dye derivative, (B) a water-insoluble dye, (C) a dispersant, and water, wherein the (A) component contains an anthraquinone-based compound represented by formula (a1), the (C) componen...
|
|
WO/2020/198368A1 |
The present disclosure relates to compounds, pharmaceutical compositions comprising such compounds, and use of such compounds in methods of treatment or in medicaments for treatment of inflammatory diseases and certain neurological disor...
|
|
WO/2020/192562A1 |
Provided are a substituted heterocyclic amide compound having a selective inhibitory effect on RIPK1, and a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof, and a pharmaceutical composition containing the...
|
|
WO/2020/195588A1 |
Provided are an actinic-light-sensitive or radiation-sensitive resin composition that has high resolution ability and is capable of preventing device contamination, as well as an actinic-light-sensitive or radiation-sensitive film, patte...
|
|
WO/2020/191205A1 |
Compounds and methods are provided for inhibiting a PI4-kinase. Methods of treating a pathogen infection and methods of treating cancer are also provided. The PI4-kinase inhibitor can be a compound that is a 5-aryl or heteroaryl-thiazole...
|
|
WO/2020/191348A1 |
Therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A and arginine gingipain B, are disclosed, as well as the use thereof for the treatment of disorders associated with P. gingivalis ...
|
|
WO/2020/186006A1 |
This application is directed to inhibitors of RAD51 represented by the following structural formula, (I), and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
|
|
WO/2020/176863A1 |
Provided herein are secretion inhibitors, such as inhibitors of Sec61, methods for their preparation, related pharmaceutical compositions, and methods for using the same, wherein the compound has a structure of Formula (I), (II), or (III).
|
|
WO/2020/176424A1 |
The present disclosure relates generally to compounds that simultaneously bind both mutant huntingtin protein (mHTT) and an ubiquitin E3 ligase and their use as therapeutic agents, for example, in treating diseases, such as neurodegenera...
|
|
WO/2020/171221A1 |
The purpose of the present invention is to provide an organic EL element in which a capping layer is combined with various materials of the element so that properties of each of the materials of the element can be effectively demonstrate...
|
|
WO/2020/168152A2 |
Disclosed are compounds of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein Q is a 5-membered heterocyclyl or 5-membered heteroaryl having 1 to 4 heteroatoms independently selec...
|
|
WO/2020/165403A1 |
Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as a pesticides, especially as fungicides.
|
|
WO/2020/164403A1 |
A 1,1-dicyano-oxime-ether compound, having a structure as represented by general formula I. The compound of general formula I has excellent bactericidal activity, and has good prevention and control effects on plant bacterial diseases an...
|
|
WO/2020/160332A1 |
Provided herein are crystalline forms of 2-(2-(2-(2-(4-(benzo[d]thiazol-2-yl)phenoxy)ethoxy)ethoxy)et
hoxy)ethan-l-ol (Compound I): Also provided are processes of manufacture and methods of using the crystalline forms.
|
|
WO/2020/157069A1 |
The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inh...
|
|
WO/2020/160295A1 |
The present invention relates to bi-functional compounds which function to recruit endogenous proteins to an E3 ubiquitin ligase for degradation, and methods for using same. More specifically, the present disclosure provides specific pro...
|
|
WO/2020/156512A1 |
Disclosed in the present invention is an aromatic (hetero)cyclic ether compound having insecticidal activity, or an optical isomer, cis-trans isomer, or agrichemically acceptable salt thereof. Also disclosed in the present invention is a...
|
|
WO/2020/156298A1 |
Disclosed by the present invention is an application of a malononitrile compound as represented by general formula I as a bactericide. See the description for the definition of each substituent in the formula. The compound represented by...
|
|
WO/2020/158870A1 |
The purpose in one embodiment of the present invention is to provide a therapeutic for Parkinson's disease, etc. A compound represented by formulas (1), (2), or (8) or a pharmacologically acceptable salt thereof can be used in the treatm...
|
|
WO/2020/154499A1 |
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: (Formula AA) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
|
|
WO/2020/151687A1 |
Provided is an N-benzyl-N-arylsulfonamide derivative, which is an N-benzyl-N-arylsulfonamide compound represented by a general formula (I), or a pharmaceutically acceptable salt or solvate thereof. The N-benzyl-N-arylsulfonamide derivati...
|
|
WO/2020/151686A1 |
Provided in the present invention are an N-heteroaryl sulfonamide derivative, the preparation and use thereof. The N-heteroaryl sulfonamide derivative is an N-heteroaryl sulfonamide compound shown in general formula (I) or general formul...
|
|
WO/2020/147739A1 |
The present invention belongs to the technical field of pharmaceutical chemistry, and specifically relates to lysophosphatidic acid receptor antagonists and a preparation method therefor. The compounds of the present invention have high ...
|
|
WO/2020/148617A1 |
The present invention disclosed 3-substituted phenylamidine compounds of general formula (I), wherein R1, R2, R3, R4, R4a, R4b, A and E have the same meanings as defined in description. The present invention further discloses methods for...
|
|
WO/2020/148619A1 |
The present invention relates to novel heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates...
|
|
WO/2020/146822A1 |
Provided are specific leukotriene synthesis inhibitor compounds and pharmaceutical compositions comprising the compounds and methods of using the compounds and the pharmaceutical compositions in treating, for example, inflammatory diseas...
|
|
WO/2020/146657A1 |
Methods of treating a subject for cancer using a PI4-kinase inhibitor are provided. Also provided are methods of inhibiting PI4-kinase in a cancer cell to reduce cellular proliferation. The PI4-kinase inhibitor can be a compound that is ...
|
|
WO/2020/146810A1 |
Provided herein are thiazolidinedione analogues that are useful for treating non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), diabetes, and other metabolic inflammation-mediated disease and disorders.
|
|
WO/2020/142865A1 |
Disclosed in the present invention are a Benzamide compound, intermediates, a preparation method, and an application. The present invention provides a Benzamide compound as represented by formula I, and pharmaceutically acceptable salts,...
|
|
WO/2020/141514A1 |
The present invention provides a process for preparing a compound of formula [I] from a compound of formula [II] using an oxidizing agent and a catalyst, the process is carried out at a low temperature.
|
|
WO/2020/141195A1 |
The present invention relates to a compound of general formulae (I) and their use as reagents
|
|
WO/2020/130214A1 |
The present invention relates to novel hydrazone derivatives with an aryl or heteroaryl group substituted at the terminal amine group thereof and a use thereof.
|
|
WO/2020/132496A1 |
In some aspects, the present disclosure provides compounds of the formulae: (A), (B), (III), and/or (IV), wherein the variables are as defined herein. Pharmaceutical compositions of the compounds are also provided. In some aspects, the c...
|
|
WO/2020/132378A2 |
This invention, in at least some embodiments, relates to an inventive molecule, compositions comprising same, and methods of use thereof for treatment of a neurological disorder.
|
|
WO/2020/119616A1 |
Disclosed are a class of sulfonamide substituted compounds and the use thereof. Specifically, provided are compounds as shown in general formula (I) below. The compounds of the present invention have a selective inhibitory effect on Nav1...
|
|
WO/2020/121823A1 |
The present invention addresses the problem of providing: a liquid crystal composition which is to be used in an active drive display element and improves chromatic dispersion properties; a display element which uses said liquid crystal ...
|
|
WO/2020/109509A1 |
Compounds of the formula (I), wherein the substituents are as defined in claim 1, useful as pesticides, and especially fungicides.
|
|
WO/2020/108500A1 |
Provided are a histone acetylase p300 inhibitor and a use thereof, belonging to the field of medicinal chemistry technology. A compound represented by formula (I), or a stereochemical isomer thereof, or a solvate thereof, or a pharmaceut...
|
